Stayble Therapeutics AB is a Swedish life science SME developing an injectable treatment (STA-363) for chronic low back pain (cLBP) caused by spinal disc degeneration.
STA-363 aims to considerably reduce the patient´s pain in the long-term. Stayble’s patent-pending offers a cost-effective disease modifying long-term treatment option to bridge the gap in available treatment options for cLBP.
CLBP is one of the costliest and most disabling conditions globally affecting the lives of over 50 million people in the EU and U.S., with the total costs for society in the U.S. alone 100 B$-200 B$. Over two thirds of patients with discogenic cLBP are not helped by the conservative treatment options of painkillers and physiotherapy; and only a small fraction are eligible for a spinal fusion surgery, the last line of treatment.
How we reached the goals
The project focuses on gaining in-depth market understanding on the patient side as well taking a better look at potential partners. Spinverse strongly supported in project planning, proposal writing and evaluation of the quality of the proposal before submission.
The achieved 50 000 € grant from Horizon 2020 SME instrument phase 1 call will allow Stayble to strengthen and provide future direction for company’s business plan and commercialization strategy.